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INTRODUCTION
Chronic kidney disease (CKD) is associated with abnormal bone
and mineral metabolism, resulting in systemic vascular calcification.
Phosphorus retention is a major harmful complication of CKD that
leads to ectopic calcification and significant risk of cardiovascular
morbidity and mortality (1-5). Secondary hyperparathyroidism, in-
duced by hyperphosphatemia and 1,25-(OH)2 vitamin D3 deficiency,
is accompanied by parathyroid hyperplasia and excessive synthesis
and secretion of parathyroid hormone, which results in renal osteo-
dystrophy (4-6). These pathologies have established the concept of
CKD-mineral and bone disorder (CKD-MBD), which recognizes
that CKD leads to higher morbidity and mortality due to cardiovas-
cular disease and poor life prognosis (1, 2, 4). In response, a treat-
ment strategy that emphasizes life prognosis has been recom-
mended throughout the world. It is considered important to control
the blood concentrations of phosphorus and calcium within the nor-
mal range in end-stage CKD patients (1-3).
Hyperphosphatemia is treated with drug therapy as well as with
diet therapy. The drugs used in this context are adsorbents that
absorb dietary phosphorus in the digestive tract and excrete it in
the feces (7, 8). However, each of these drugs has side effects that
require diet therapy with a phosphorus-restricted diet to ensure the
safest and most reliable treatment (9, 10). In the present study, we
focused on wakame (Undaria pinnatifida), which has a variety of
biological functions in health and disease.
Wakame (U. pinnatifida), which is traditionally eaten more often
in Japan than in the rest of the world (11), is useful as a source of
minerals and dietary fiber (12).
The dietary fiber found in seaweed species amounts to 30% of dry
weight and includes alginic acid and fucoidan (AF), which have a
chemical structure different from that of the dietary fiber found in
vegetables and grains (12). Alginic acid, a viscous polysaccharide,
is a viscous component of seaweed that can be obtained from brown
algae as well as from wakame (13). Fucoidan is the generic name
for polysaccharides that contain a monosaccharide called L-fucose
as their principal component (14, 15). Fucoidan also contains D-
glucuronic acid, D-galactose, D-mannose, and sulfate groups in
constituent sugars (16, 17). Fucoidan extracted from wakame has
anti - inflammatory (18), immunomodulatory (19), antitumor (20),
and anticoagulation activities (21) and organ protective effects that
include protection of the digestive tract (17). In the present study,
we investigated the effect of wakame on the control of plasma levels
of inorganic phosphate (Pi) in normal rats and rats experiencing
chronic renal failure.
MATERIALS AND METHODS
Materials
Wakame (brand name is Hamamidori), alginic acid, and fucoidan
(fucoidan isolated from Mekabu (thick wakame leaves) were ob-
tained from the Riken Vitamin Co., Ltd. (Tokyo, Japan).
Animals
Normal Wistar rats and 5/6 nephrectomized (5/6NX) rats were
purchased from Shimizu Laboratory Supplies Co., Ltd. (Kyoto,
Japan). The (5/6NX) rats were established by general method (22).
The 5/6 nephrectomy was performed at the age of 7 weeks under
anesthesia with sodium pentobarbital (50 mg/kg body weight, i.p.).
The operation began with ablation of approximately the entire left
kidney, and then 2/3 of the right kidney was removed by ligation
of the renal artery, vein, and ureter 1 week later. After acclimatiza-
tion (2 weeks), the 5/6NX rats were divided into two groups by the
follow-up period. Rats were maintained under pathogen-free con-
ditions and handled in accordance with the Guidelines for Animal
Experimentation of Doshisha Women’s College of Liberal Arts.
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Animal Diets
Rats were fed AIN93-G, a standard diet for growth period, preg-
nant period, and lactating period, obtained from Oriental Yeast Co.,
Ltd (Tokyo, Japan), which was partially modified (Table 1). The
basic composition of AIN93-G includes a phosphorus concentration
of 0.3% and a calcium concentration of 0.5%. To modify AIN93-G
to achieve a high-phosphorus diet, AIN93-G was supplemented with
KH2PO4 (23, 24) and polyphosphoric acid in amounts adjusted to
achieve a final phosphorus concentration of 1.2% (Table 1). Dried
wakame was crushed into powder and then mixed with various
diets. The amount of wakame added to each feed was set at 5% (25,
26). The amount of added arginic acid and fucoidan, converted to
the amount contained in wakame, was set at 1.75% arginic acid and
0.5% fucoidan (Tables 1 and 2). Corrections associated with the ad-
dition of feed components were done with cornstarch. Following
preliminary feeding, rats were divided into two groups. The control
Pi (CP) group was fed AIN93-G (0.3% Pi ; Oriental Yeast Co., Ltd,
Tokyo, Japan) for 3 weeks, and the high-Pi (HP) group was fed
AIN93-G modified to contain 1.2% Pi for 3 weeks. Subsequently,
both groups were further divided into two groups so as to avoid
any intergroup differences in body weight. The wakame group
(CP+W or HP+W groups) had their diets supplemented with 5%
wakame, whereas the rats in the other group were fed their origi-
nal (CP or HP) diets. Rats were sacrificed at 16 weeks of age.
Biochemical analysis of blood, urine, and feces
Phosphorus concentrations in plasma, urine, and feces were
measured with the Phospho C test Kit (Wako Pure Chemical Indus-
tries, Ltd) using the p -methylaminophenol reduction method. Cal-
cium concentrations in plasma, urine, and feces were measured
with the Calcium E Test Kit (Wako Pure Chemical Industries, Ltd)
using the MXB method. Plasma and urine creatinine concentrations
were measured with the Lab Assay Creatinine Test Kit (Wako Pure
Chemical Industries, Ltd) using the Jaffe method. Blood urea ni-
trogen (BUN) concentrations were measured with the Blood Ni-
trogen B Test Kit (Wako Pure Chemical Industries, Ltd) using the
urease- indophenol method.
Statistical analyses
Data are expressed as means and standard deviations or means
and their standard errors. Statistical analyses were performed using
ANOVA. Multiple comparisons (Tukey’s test) were conducted in
cases of significant difference. Student’s t - test was used for com-
parisons between two groups.
RESULTS
Effect of wakame on plasma Pi levels in normal rats
In the first set of experiments (Figure 1A), we investigated the
effect of wakame on plasma Pi levels in normal rats. The composi-
tions of the experimental diets are listed in Tables 1 and 2. The ex-
perimental animals were fed either a HP diet (1.2% Pi ; HP group)
or a CP diet (0.3% Pi ; CP group) for 3 weeks. Each group was then
split into two ; half were fed a diet containing wakame (W), and
the other half were continued on their CP or HP diets for 4 weeks.
As shown in Figure 1B, food intake did not differ between the HP
and CP groups. Plasma Pi levels were significantly higher in the
HP group, compared with the CP group. The final concentration
of dietary Pi was slightly increased in the CP+W (0.318% Pi) diet,
compared with the CP diet (0.3% Pi). The concentrations of min-
erals (Na, K, Ca, Mg, and Pi [%]) in the various diets are listed in
Table 2. The diet containing wakame contained higher levels of Na,
K, and Mg than the control diet. However, the increased levels of
these minerals in the diet did not affect the plasma Pi concentration
in normal rats, because a control diet containing higher Na, K, and
Mg levels (wakame mineral mixture) did not influenced plasma
Pi levels in normal rats (data not shown). Indeed, the CP and the
CP+W groups showed normal plasma Pi levels (Figure 1C). In
contrast, the animals fed a HP diet for 7 weeks showed signifi-
cantly higher plasma Pi levels than those fed a normal Pi diet. In
the animals fed a HP diet containing wakame (the HP+W group),
plasma Pi levels were significantly reduced compared with the HP
group (Figure 1C). These data suggest that the diet containing
wakame prevented the hyperphosphatemia induced by a HP diet.
Effect of wakame on urinary and fecal Pi levels in normal rats
To address the mechanisms of wakame’s plasma Pi lowering
effect, we analyzed urinary and fecal Pi levels. If wakame prevents
the intestinal absorption of Pi, the experimental animals should
show a reduction in urinary Pi levels and an increase in fecal Pi
levels. Urinary Pi excretion levels were significantly increased in
the HP group, compared with those in the CP group (Figure 2A).
This occurred because feeding a diet containing high amounts of
Pi stimulates urinary Pi excretion. Comparing the CP+W group
with the CP group, urinary Pi excretion levels were not changed
(Figure 2A). In contrast, urinary Pi excretion levels were signifi-
cantly decreased in the HP+W group, compared with the HP group
(Figure 2A). In the HP+W group, fecal Pi levels were significantly
increased to about 1.65- fold that of the HP group (Figure 2B).
Table 1. Composition of the experimental diets
CP CP+W HP HP+W HP+AF
Cornstarch (g) 39.7486 34.7486 36.0620 31.0620 33.8120
Casein (g) 20.0000 20.0000 20.0000 20.0000 20.0000
α -cornstarch (g) 13.2000 13.2000 13.2000 13.2000 13.2000
Sucrose (g) 10.0000 10.0000 10.0000 10.0000 10.0000
Soy oil (g) 7.0000 7.0000 7.0000 7.0000 7.0000
Cellulose (g) 5.0000 5.0000 5.0000 5.0000 5.0000
Mineral Mix(1)(g) 3.5000 3.5000 3.5000 3.5000 3.5000
Vitamin Mix(2) (g) 1.0000 1.0000 1.0000 1.0000 1.0000
L-Cystine (g) 0.3000 0.3000 0.3000 0.3000 0.3000
Choline bitartrate (g) 0.2500 0.2500 0.2500 0.2500 0.2500
Tertiary butylhydro-
quinone (g) 0.0014 0.0014 0.0014 0.0014 0.0014
KH2PO4 (g) 0.0000 0.0000 3.0755 3.0755 3.0755
P2O5 (g) 0.0000 0.0000 0.6111 0.6111 0.6111
Wakame (g) 0.0000 5.0000 0.0000 5.0000 0.0000
Arginic acid (g) 0.0000 0.0000 0.0000 0.0000 1.7500
Fucoidan (g) 0.0000 0.0000 0.0000 0.0000 0.5000
Total (g) 100.0000 100.0000 100.0000 100.0000 100.0000
(1) AIN-93G Mineral Mixture (2) AIN-93G Vitamin Mixture
Table 2. Comparison of the minerals in experimental diets
CP CP+W HP HP+W HP+AF
Na (%) 0.103 0.433 0.103 0.433 0.103
K (%) 0.334 0.594 1.218 1.478 1.218
Ca (%) 0.5 0.539 0.5 0.539 0.5
Mg (%) 0.051 0.106 0.051 0.106 0.051
Pi (%) 0.3 0.318 1.2 1.218 1.2
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These data show that intestinal absorption of Pi was significantly
decreased in the HP+W group, compared with the HP group. This
suggests that the reduced absorption of intestinal Pi is a primary
mechanism for the decrease in plasma Pi levels seen in the animals
fed a diet containing wakame.
Effect of wakame components on the progression of CKD
Next to investigate the effect of wakame on the progression of
renal failure, we used 5/6NX animals fed a HP diet (22) (Figure
3A). In this model, feeding a HP diet to 5/6NX rats accelerates
renal damage. We compared the biochemical parameters of the
HP with those of the HP+W group. Food intake did not differ be-
tween the HP+W and HP groups (Figure 3B). Plasma Pi levels
were significantly decreased in the HP+W group, compared with
the HP group (Figure 3C). Although urinary Pi excretion levels
were the same in the HP+W and HP groups (Figure 3D), fecal Pi
levels were increased about 1.55- fold in the HP+W group, com-
pared with the HP group (Figure 3E). The BUN levels, a parameter
of kidney function, were significantly reduced in the HP+W group
(Figure 3F). These data show that, in a model of CKD, feeding a
diet containing wakame inhibits the progression of renal failure and
hyperphosphatemia.
Effect of wakame fiber components, AF, on plasma Pi levels
We performed a search to identify the components of wakame
that lower the plasma Pi level. Because fiber accounts for 30% of
Figure 1. Plasma Pi levels are decreased by wakame in normal rats fed a high-Pi diet.
(A) A schematic of the experimental design that defines the various diet groups. CP : Control Pi (AIN93-G) diet used to establish normative parame-
ters. CP+W : CP diet supplemented with 5% wakame. HP : AIN93-G diet supplemented to contain 1.2% Pi. HP+W : HP diet further supplemented
with 5% wakame. CP and HP groups were fed CP or HP diet for 3 weeks. Subsequently, both groups were further divided into two groups (includ-
ing 5% wakame or not) so as to avoid any intergroup differences in body weight at 8 weeks of age. Rats were fed this diet for the next 4 weeks.
(B) Food consumption in the various diets groups measured at 12 weeks age. (C) Plasma Pi levels analyzed at 12 weeks of age. Data are presented
as meanSEM (n=6/group). *P0.05
Figure 2. Effect of wakame on urinary and fecal Pi levels.
(A) The experimental design followed that shown in Figure 1A. Urinary Pi/urinary creatinine (cre). (B) Fecal Pi/Pi consumption was analyzed at
12 weeks of age. Data are presented as meanSEM (n=6/group). *P0.05 ;**P0.01.
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the total components of dry wakame, we prepared diets containing
levels of AF that are the same as those found in the diets contain-
ing wakame. The amounts of alginic acid (A) and fucoidan (F) in
each diet containing HP are listed in Table 1. We then investigated
whether the fibers found in wakame, AF, reduce plasma Pi levels
in the CP and the HP groups (Figure 4). In the CP+AF and the
HP+AF groups, plasma Pi levels were significantly reduced com-
pared with those in the CP and the HP groups (Figure 4A and B).
These data suggest that AF reduce plasma Pi levels in normal rats.
Figure 3. Effect of wakame on plasma Pi levels on 5/6 nephrectomized rats.
(A) A schematic of the experimental design defining the various diet groups. HP : AIN93-G diet supplemented to contain 1.2% Pi. HP+W : HP further
supplemented to contain 5% wakame. (B) Food consumption by rats of each diet. (C) Plasma Pi levels. (D) Urinary Pi/creatinine (cre). (E) Fecal
Pi/Pi consumption. (F) Serum BUN levels. These parameters were analyzed at 16 weeks of age. Data are presented as meanSEM. (n=6/group).
**P0.05 ;**P0.01.
Figure 4. Effect of alginic acid and fucoidan as wakame fiber on plasma Pi levels in normal rats.
(A) A schematic of the experimental design defining the various diet groups. CP : Control Pi (AIN93-G) diet used to establish normative parameters.
CP+W : CP diet supplemented with 5% wakame. CP+AF : CP diet supplemented with alginic acid (1.75%) and fucoidan (0.5%). HP : AIN93-G diet
supplemented to include 1.2% Pi. HP+W : HP diet further supplemented with 5% wakame. HP+AF : HP diet further supplemented with 1.75% alginic
acid and 0.5% fucoidan. (B) and (C) Plasma Pi levels. Data are presented as meanSEM. **P0.01 (n=4-6/group)
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DISCUSSION
Hyperphosphatemia has been identified in the past decade as a
strong predictor of mortality in patients with advanced CKD (4, 27,
28). More recent studies have shown that the association between
HP concentrations and higher mortality is not restricted to persons
with renal disease ; it can also be observed in persons with cardio-
vascular disease and even in the general population (29). Current
strategies for the treatment of hyperphosphatemia in dialysis pa-
tients include dietary phosphate restriction and oral phosphate
binders, although these treatments, if used aggressively, can lead
to malnutrition, adverse gastrointestinal effects, and poor compli-
ance with all medications, particularly in the elderly (7). As an al-
ternative, a number of studies have shown that bioactive compounds
extracted from natural products have some therapeutic potential for
hyperphosphatemia. We previously reported that nicotinamide (an
amide derivative of the water-soluble vitamin B3) is a potentially
interesting alternative to phosphate binders (30, 31). We demon-
strated that nicotinamide reduces hyperphosphatemia by inhibit-
ing a sodium-dependent phosphate co-transporter in the kidney
and small intestine (30, 31). Therefore, discovering foods or nutri-
ents that inhibiting Pi absorption may be useful for the treatment
of hyperphosphatemia.
In the present study, we investigated the plasma Pi lowering
effects of wakame, as well as wakame’s effect on the progression
of renal failure. Wakame (U. pinnatifida) is a food that is tradition-
ally eaten more often in Japan than in the rest of the world. The
fiber in seaweed species amounts to 30% of dry weight and includes
AF, which have chemical structures different from those of the die-
tary fibers found in vegetables and grains. In recent toxicological
reports, fucoidan derived from U. pinnatifid and Laminaria japon-
ica was found to be safe in animal models at very high levels of in-
take (32, 33). In addition, wakame is a useful source of sodium,
potassium, and magnesium (34). These factors may not be involved
in the prevention of hyperphosphatemia, because the elevation of
total mineral content in the experimental diets did not affect plasma
Pi levels (data not shown). Therefore, we hypothesized that die-
tary fiber may be involved in the prevention of hyperphosphatemia
in animals with CKD.
In normal animals, diets containing 5% wakame significantly de-
creased plasma Pi levels and urinary Pi excretion. The diet contain-
ing 5% wakame also prevented the progression of renal failure. Ani-
mals fed the diet containing wakame showed a significant increase
in fecal Pi excretion. We suggest that this effect may be due to a
reduction in plasma Pi levels or uremic toxins. Indeed, wakame has
many functional elements for toxin binding (35). In the present
study, wakame lowered plasma Pi levels by preventing the absorp-
tion of intestinal Pi and prevented the progression of renal failure.
Wakame may be useful food for the prevention of hyperphos-
phatemia.
Alginic acid is a viscous component of seaweed that can be ob-
tained from brown algae as well as from wakame. It is a polysac-
charide with an α, β1-4 coupling involving D-mannuronic acid and
L-glucuronic acid (13). Alginic acid is famous for its metal chelat-
ing ability and is used widely as a healthy food because of its bene-
ficial functions (13). Studies of the effect of alginic acid on mineral
absorption have been reported. Hodgkinson et al. reported its inter-
ference with calcium absorption in humans (36). Alginic acid also
increases fecal losses of copper, iron, and zinc in rats (37, 38). In
addition, low molecular weight sodium alginate inhibits reabsorp-
tion of bile acid by binding to bile acid in the small intestine and
causing its excretion in the feces (39).
The study of this process has shown that bile acid is synthe-
sized from the cholesterol to supplement the bile acid lost because
of inhibited reabsorption, and, as a result, the plasma cholesterol
level is lowered (39, 40).
Fucoidan is the generic name for polysaccharides containing the
monosaccharide L-fucose as their principle component. Fucoidan
also contains D-glucuronic acid, D-galactose, D-mannose, and sul-
fate groups in constituent sugars (17). Recent in vivo and in vitro
clinical research shows that fucoidan is useful to control acute and
chronic inflammation via selectin blockade, enzyme inhibition, and
inhibition of the complement cascade (41). Fucoidan is also known
to increase the activity of fibroblast growth factor by binding and
to have an anticancer effect (42, 43). Although we have not ana-
lyzed the mechanisms of alginic acids and fucoidan on lowering
of plasma Pi levels, there are several possibilities on the lower-
ing effect of plasma Pi by both factors.
Recent studies indicate that the intestinal sodium-dependent
phosphate co-transporters Npt2b are a major target for the preven-
tion of hyperphosphatemia in animal models of CKD (44-46). In-
deed, Npt2b knockout mice show resistance to hyperphosphatemia
in CKD models (45). The N-glycan of the Npt2 family transporters
is important in their function and cellular localization. Recent studies
showed that klotho modifies the N-glycan of Npt2a/b, thereby in-
hibiting Na-dependent Pi co-transport activity (47). Klotho hydro-
lyzes β -glycosides and is a β -D-glucuronidase inhibitor (48).
Chang et al. proposed that klotho activates TRPV5 via its β -glucu-
ronidase activity (48). The Mekabu fucoidan commonly used con-
tains a high proportion of galactose (17). Therefore, these compo-
nents may be involved in the modification of activities mediated by
the N-glycan of Npt2b in the small intestine (data not shown). This
study is the first report that Wakame has ameliorating effect for
hyperphosphatemia in rats experiencing renal failure. Further stud-
ies are needed to clarify the lowering effect of AF on plasma Pi
levels in CKD models. Finally, in the present study, we showed that
wakame is a useful food for the prevention of hyperphosphatemia
in an animal model of CKD.
ABBREVIATIONS
Pi inorganic phosphate
CKD chronic kidney disease
CKD-MBD CKD-mineral and bone disorder
AF alginic acid (A) and fucoidan (F)
5/6NX 5/6 nephrectomized
CP control phosphate
CP+W control phosphate+wakame
HP high phosphate
HP+W high phosphate+wakame
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